You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百济神州(06160.HK)获Boston Immune授予开发独家选择授权
阿思达克 02-18 09:15
百济神州(06160.HK)公布,与美国Boston Immune Technologies and Therapeutics, Inc(BITT)达成一项选择和授权协定,百济神州已经获得BITT专利保护的TNFR2拮抗剂抗体、於亚洲(日本除外)、澳洲及纽西兰的独家开发、生产和商业化授权选择权。

双方计划启动多项1期临床试验,以评估BITT的先进TNFR2拮抗剂抗体BITR2101,包括其联合百济神州抗PD-1抗体「百泽安」(替雷利珠单抗)的组合用药研究。

根据协议条款,BITT将获得共计1,660万美元的预付款及近期里程碑付款,其中包括百济神州在概念验证研究后行使选择权。此外,在百济神州行使选择权后,BITT有资格获得至多为1.05亿美元的开发、注册及销售里程碑付款,另加在授权地区的分级产品销售特许使用费。

连同该项独家选择和授权协定,百济神州同时参与BITT的A轮优先股融资,涉及投资400万美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account